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This paper examines the recent development of biotechnology related industry in the 
Finnish city of Turku. The basic aim of the paper is to identify the different 
technological, economic and institutional factors that have enabled the rapid 
development of the biotechnology industry. From a regional point of view the paper 
tries to bring forth the factors that have activated the local community to actively pursue 
the development process and how this process compares with similar processes 
elsewhere. Lastly the present state and future challenges of the local industry 
concentration are analysed briefly.   
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Introduction 
Turku is situated in the southwest corner of Finland and has a population of 
approximately 250,000 people, if we generously count n not just the city itself, but the 
region around Turku comprising the towns of Salo, Kaarina, and Raisio etc. The city of 
Turku city itself is a population of 173,000. Turku is 160 km west from Helsinki and 
320 km by sea from Stockholm. Throughout the history, the city has been one of the 
major ports in Finland and especially connections with Sweden have been dense. The 
traditional industries in the city have been metal work, shipbuilding, real estate services 
and construction, food and pharmaceutics and graphics/printing.  
This paper examines the recent development of biotechnology related industry in 
Turku. The growth of biotechnology related activities has grown rapidly and especially 
pharmaceutical industry has adopted the use of post-1970s molecular biology 
breakthroughs in “biotechnology”. Finland is now listed in numbers of biotech firms as 
the 7th largest in Europe (Ernst & Young 2001) and Turku is the second biggest 
concentration of biotechnology related activities in Finland. The interest of study is to 
scrutinise the dynamics behind the development as a combination of technological, 
institutional and economic factors. The main objective of this study is to focus on the 
link between technology and institutions but also on the role of different organisations  
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in the process of building capability to produce new innovations and new industrial 
activity. 
The paper claims that the rapid development of the biotechnology industry in the 
1990s in Turku arises from a much older story, with historical capabilities been 
gradually built up especially within pharmaceuticals over decades both in industry and 
university research. Many external factors have also had a big influence in triggering the 
development process. These involve factors like the global structural change in the 
pharmaceutical industry, the internationalisation of trade, the recession in Finland in the 
early 90s and the substantial changes in the national innovation system.  
A specific focus in the study has been the interaction between universities and 
companies, which is one of the key factors in a science based industry like 
biotechnology. Our findings suggest that the interaction has been primarily driven and 
institutionalised by larger pharmaceutical and diagnostic companies in the past, and 
more recently by smaller start-ups and spin-offs. The latter do not have large corporate 
R&D capabilities and must thus depend to a greater extent on external research links. 
From the university point of view, the interaction has been more based on resource 
constraints than a dedicated strategy for developing co-operation in the field of 
biotechnology. 
From the policy standpoint, the development of the innovation system in Turku to 
support a new technology area has been different from many other Finnish cities, in a 
way that the local public sector has not played a very active role in the beginning. For a 
long time, the mobilising of local resources and the successful attempts to influence 
national S&T policy have mainly been a result of a network of individuals working in 
the industry and in the universities rather than a general strategy of the universities or 
the local government. More recently, the City of Turku has been much more active and 
even instrumental in building new institutions and infrastructure to support the growth 
of the new industry. 
Thus, the rise of Turku should be seen as building on older capabilities, recently 
driven forward by new institutions that have come about due to resource constraints, 
external economic shocks and fundamental changes in the global pharmaceutical 
industry. The new ‘BioTurku’ has arisen, therefore, more as a reconsolidation of 
expertise across sectors under a new banner of “biotech”, which has in turn, allowed 
new configurations of innovative actors to link up and create new technological services 
and products as well. As a result, a variety of earlier unrelated sectors in food,  
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pharmaceuticals and materials sciences, have now been pulled together with a common 
technological base. This development has also made it easier for the policy makers to 
formulate a focused strategy for local innovation policy. 
The study is based on written documents, statistical data and total of 36
1 interviews. 
Interviews were conducted with academics, policy makers at various levels, CEO and 
R&D heads of companies, as well as business managers. Within the “biotech” industry 
of Turku, broadly defined. Specifically, the focus was on pharmaceutical (therapeutic) 
firms involved in drug discovery, development and manufacturing. A central difference 
with previous studies of Turku2 is that this study focuses more broadly on the link 
between technology, economy and institutions, in other words, which institutions and 
events organisations might have been central to the process of building capability and 
opportunities for a new industry to emerge and grow. 
Biotechnology industry in Turku and in Finland 
Biotechnology has developed as one of the fastest growing industries in Finland. It has 
been selected as one of the key development areas in the national policies and many 
resources have been directed to the development of both research and industry during 
the past 15 years.   
In Finland as a whole, the biotech industry in 2000 was broadly categorised into the 
development of medicine (no. of companies 17), large medical companies-Orion, Leiras 
and Santen (3), diagnostics (30), biomaterials (9), food (12), industrial enzymes (3), 
agro (6), services (28), others (15), for a total of 123 biotech-related companies 
nationwide in 1999. The turnover was 1860 million €. However, excluding the top three 
large companies, the turnover was 663 million €. The employment numbers also 
demonstrate the dominance of the large pharmaceutical companies: the total 
employment in the biotech sector within these 123 firms was 10,813, but excluding big 
pharma was only 4, 178. (Source: FinBio) 
In 2000, the Finnish turnover of “life-science” industries was1.4% of GNP and 2.1% 
of industrial employment (0.4% total employment) and 2/3 of this was in the 
pharmaceutical industry. (Tulkki et al 2001). From a sectoral standpoint, pharmaceutical 
production in Finland in 1998, for example, was €575 million compared to €15,980 
                                                 
1 The interviews were part of the international LIS project and were conducted together by Kimmo 
Viljamaa and Smita Srinivas from MIT Industrial Performance Center.  
2 Primarily those of Bruun 2002a, 2002b and Bruun et al 2001.   
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million for the Finnish electrical and electronic industries in the same year, or about 
5.75 % of the electrical and electronic industries’ production figures. At the same time, 
the natural and medical sciences jointly published 85.3% of all Finnish academic 
publications in 1999 compared to 7% in engineering and technology areas. However, 
with the blurring of engineering and life science areas in biotechnology fields, these 
publication categories and figures may change. However, if sites for clinical trials and 
the new chemical entities (NCEs) they introduce into the market are anything to go by, 
then Finland has a strong advantage. It introduced 8.6% NCEs introduced in clinical 
trials, had 0.4% of the world pharmaceutical market and 0.1% of the world’s population 
in 1998. (Brännback et al 2001a, 50) 
Turku is the second biggest concentration of biotechnology activities in Finland after 
Helsinki. Other regions with dedicated centres for developing biotechnology are Oulu, 
Tampere and Kuopio. Moreover, there are also many universities with biotechnology 
related research and education in Finland. In the Finnish perspective, Turku region is 
especially strong in biopharmaceuticals, but also has activities in diagnostics, 
biomaterials and functional foods. 
The primary specialisation of firms within the Turku biotech cluster in 1999-2000 
was in diagnostics and input materials (35%), followed by pharmaceutical product 
development (29%), services –research, marketing and consulting (22%), biomaterials 
and functional foods (7% each). The 1996-2000 period saw the sharpest rise (~65) in 
new biotech firms in Finland and the development seems to have been very similar also 
in Turku. Companies started in the 1998-2000 period were broadly categorised as 
biomedicine (37%), diagnostics (31%), biomaterials (13%) and others (19%) (Orava et 
al 2001 and FinBio).  
The pharmaceutical industry is especially strong in Turku. There are two bigger 
pharmaceutical companies present in the city, Schering and Orion. Both of these 
companies do R&D in Turku. There are also quite many smaller drug discovery 
companies like BioTie Therapies, Hormos Medical, Juvantia Pharma etc. Together with 
the universities and service companies, this sub-field forms a relatively tight network of 
drug development. Most of the smaller companies have appeared during the last ten 
years and the number of companies has increased rapidly.  
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The territorial agglomeration of industrial activities and biotechnology 
The approach of the study is to focus on the local concentrations of a particular industry 
– in this case biotechnology related activities. The local (or regional/territorial) aspect 
has been seen as an important factor in explaining the development of industrial 
activities. Industry has the tendency to concentrate in certain locations, which affects the 
nature of innovation and industrial activities in many ways. 
There have been studies focusing on territorial agglomeration for decades, dating 
back to late 19
th and early 20
th century and the works of Marshall (see Simmie 2001; 
Malmberg & Maskell 2001; Moulaert & Sekia 2003) and Weber on the economics of 
agglomeration. According to Malmberg & Maskell (2001) we can find at least three 
traditional factors that affect spatial clustering. The traditional analysis of spatial 
clustering tries to analyze the advantages that firms get by locating close to each other 
(localization economies). Three different mechanisms have been traditionally identified: 
1.  Reduced costs to produce and maintain a dedicated infrastructure and other 
collective resources 
2.  Well-functioning markets for specialized skills 
3.  Reduced interaction costs for co-located trading partners 
During the last few decades the special focus in these studies has been focused in 
explaining the relation between the spatial clustering of firms and the innovation 
process. Several different approaches have been developed, amongst them Innovative 
Milieu, New Industrial Spaces, Spatial Clusters of Innovation, Regional Innovation 
Systems and Learning Regions (Moulaert & Sekia 2003). The increased interest can be 
seen as a result of the change in the nature of economic activities as a result of 
technological change and globalisation. There is talk about information economy, 
knowledge economy, learning economy etc.  
Increasing pressures like world markets, competition, ICT push companies to find 
new ways of competitiveness. At the same time there are increasing opportunities 
provided to increase scientific development and new ways to use ICT. This similar 
influence of external pressures and opportunities leads to a very turbulent environment 
for the firms (Schienstock & Hämäläinen 2001). There are usually two ways in which 
the companies respond to this development: specialisation and innovation. They 
outsource everything they are not best in and with innovation they try to maximize the 
profits of their core competencies. Both of these developments lead in many situations 
to increasing local (as well as global) connections. Many services, external functions  
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have to operate close by (the economics of scale and time, transaction costs etc.). With 
innovation, the central factor is knowledge generation and transfer, where companies 
locate near the knowledge sources and each other (time economics, tacit knowledge 
etc.).  
What is essential in this ‘new phase’ is the increasing role of knowledge, learning 
and innovations as the source of competitiveness. The recent analysis of spatial 
clustering is based on the idea of knowledge and innovation, which brings forth a new 
factor for spatial clustering: 
4.  A localized cluster of firms that form a basis for the local milieu that may facilitate 
knowledge spillovers, learning and adaptation. 
The general argument is that local industrial structures with many firms competing in 
the same industry or collaborating across related industries tend to trigger processes, 
which create not only dynamism and flexibility in general, but also learning and 
innovation. A local culture with specific norms, values and institutions (formal and 
informal) makes it also possible to transfer tacit forms of knowledge from one actor to 
another. The cluster is seen to exist because the co-location of firms cut the expenses of 
identifying, accessing and transferring knowledge (Malmberg & Maskell 2001). 
Although a shared infrastructure and supplier and service network have an important 
role, in a high tech industry like biotechnology, the role of knowledge becomes 
especially crucial. Several reasons related to knowledge and expertise that link 
innovation capability to space can be found. 
−  New knowledge. New knowledge is usually difficult to codify and therefore 
difficult to transfer. It is best transferred through repeated and frequent face-to-face 
contacts. Innovation is therefore facilitated by geographical proximity. 
−  Knowledge exchange. Knowledge exchange can happen through knowledge 
spillovers. On the other hand, most actors are unwilling to share crucial information 
when there is a danger that it can end up in the hands of the competitors. 
Information exchange usually happens with known and trusted clients and 
customers. This may also be the case with long-term co-operation with the 
universities and research institutions. 
−  The availability of a high level workforce is a very important requirement for 
innovation. Labour mobility is lower (especially in Europe) than the mobility of 
other resources and tends to concentrate in certain regions. 
Innovation and industry structure in biotechnology 
The nature of the agglomeration of innovative activities depends on the industry. First 
of all, biotechnology has until today been very much dominated by the US and to a  
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lesser extent in Europe, by U.K. (see Breschi et al 2001, 1). Biotechnology activities 
also tend to concentrate strongly in specific areas. This concentration goes even so far 
that a few local concentrations of activities (like Cambridge, MA. and San-Fransisco-
San Jose, CA.) are globally in a dominant position (Cooke 2002, 5) 
 What is important to see is that the nature of an industry and technology has a big 
influence on the development process and especially the capabilities and resources that 
are needed for a new industry to develop successfully in a given location. From the 
R&D point of view biotechnology is a very demanding field. The research in the 
biosciences demands rapidly evolving and expensive methods and instrumentation 
(Biotechnology in Finland 2002, 16). Because the cost of R&D is so big it puts special 
emphasis to funding, both in university research and company R&D. Biotechnology 
also often requires very time-consuming experimentation with expensive materials and 
equipment. Many of the innovations are also based on basic research, which means that 
the time from the innovation to markets is very long.   
What is important to notice in the light of biotechnology industry is the notion made 
by Cooke (2002, 11) that there is a growing evidence that university or public 
laboratory research with associated spin-off DBFs is at the heart of knowledge 
generation and exploitation. In this way, the previous world of pharmaceutical R&D 
dominated by large multinationals has changed. At the same time, the global MNCs 
increasingly specialise in distribution and marketing. In the light of the value chain it 
seems that the innovation system in biotechnology is both highly regionalised and 
globalised at the same time. 
The geographical concentration of biotechnology can be seen as the concentration of 
knowledge. Much of the knowledge can be found at the universities and R&D 
institutions which make these places local concentrations of knowledge and expertise 
but also potential workforce for the firms. Many of the knowledge spillovers are also 
very local by nature, either based on tacit knowledge or because people are usually 
better informed of the local knowledge base. For example in the study of Jaffe et al. 
(1993) of the commercial use of university patents it was shown that most of the use of 
university happened within 50 miles of the university. Also it has been noted that 
especially in the early phases of the exploitation of biotechnology the successful 
development required considerable amount of tacit knowledge (Zucker et al 1998) 
Of the two ‘localisation effects’ the existence of high level knowledge and research 
in the area seems to be more important factor than local knowledge spillovers in the  
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development of local biotechnology clusters. According to Cooke et al (2003) untraded 
interdependencies mentioned in many studies are not that typical for biosciences. 
Because techniques used in biotechnology are so specific and not widely known, there 
is typically not much knowledge transfer through social ties and networking between 
firms simply because knowledge is very specific.  Localisation effects originate because 
the so called ‘star scientists’ that are invaluable to R&D tend to locate near their home 
universities.  
Another factor seems to be the increasing multidisciplinary nature of biotechnology 
R&D. In many cases the development work requires a very heterogeneous set of 
cognitive skills, which leads to an increasing need for transdisciplinary network 
relationships (Orsenigo et al (2001). This calls for a concentration of a broad set of 
expertise, which can usually be found within a larger concentration of related activities. 
As what becomes to what Cooke et al (2003) call exploitation knowledge – the 
translation of basic research into applications, a few localisation factors can be found. 
Many times small DBFs are reliant on research scientists to translate the non-codified 
knowledge to them in the form that can be further developed. People with experience of 
both research and industry tend to be magnets for new companies. 
In many cases also the special services play an important role. Especially business 
services and specialised expert services tend to locate close to key customers and 
therefore can also increase the attractiveness of the location for new companies. This 
study also gives indications that even if there is little interaction and knowledge transfer 
related to actual R&D in the companies, quite a lot of interaction and exchange of 
experience takes place related to other questions like business expertise and services.  
All in all, biotech is typically a very spatially clustered industry. Biotechnology 
companies are located close to major universities, hospitals, research centres and 
sometimes with supportive bigger companies with which SMEs have interaction. At 
least in the initial phases most of the new ideas and new start-up firms seem to be 
university based. However, Feldman (2002, 14) argues that even though universities 
seem to be necessary for the development of biotech concentration, the existence of a 
high ‘knowledge base’ might not be enough. As Orsenigo (2001) argues from Italian 
experience, the existence of a strong scientific base does not guarantee that there will be 
new start-up companies and an industry will emerge. There is also no firm evidence  
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supporting that there would be a correlation between university financing or the number 
of patents and the number of start-ups (Feldman 2002, 15)  
Especially at the later stages of the industry development, the local industry can also 
be dependent on few bigger anchor firms (Feldman 2002) as the industry develops from 
‘science-stage’ towards more commercial application oriented activities. The bigger 
companies can act as pool of skilled labour and demand for special inputs that may 
benefit smaller start-ups (Feldman 2002, 14). The experienced people in the existing 
bigger firms can also act as a pool for potential entrepreneurs. 
In conclusion it can be said that especially in biotechnology the mechanisms of co-
location and spatial clustering seem to be especially strong. However, favourable 
conditions for locating do not by themselves explain the development of an industry in a 
particular region. The agglomeration advantages (e.g. strong science base, working 
labour market) in a particular locale only lay basics for the capabilities and 
opportunities for the industry to grow but there are other factors affecting the way these 
opportunities are actually realised. The structure of an industry, technological change, 
economic factors, changes in the institutional base and local development policy are all 
factors that come to play. 
Technological, economic and institutional changes in the environment 
The different factor affecting the opportunities and limits of successful cluster 
development can be in general divided into external and internal factors. External 
factors refer to different effects on the external environment. These can for example be 
changes in the world economy, the changes in the global structure of a given industry, 
technological change, large scale institutional changes like legislation, trade agreements 
etc.  
Internal factors on the other hand refer to those elements in the local environment 
that affect the competitiveness and innovation capabilities of the local firms. We can 
talk about regional or urban competitiveness. These internal factors can further be 
divided into structural and dynamic factors (Linnamaa 1999). Structural factors like the 
local infrastructure, industrial structure, living environment and local institutions are 
very important to the development of firms. In many cases, the structural elements are 
not enough, though.  
Recently there has been a lot more discussion about the dynamic elements and 
dynamic capabilities of a region. These cover among others the human resources in the  
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region, the local culture and the social environment where people live and work. These 
factors affect the way information and knowledge is transferred in the local networks, 
how supportive the environment is to entrepreneurship etc. There is talk about local 
buzz, the kind of ongoing processes in the local environment that strengthens 
information exchange and gives new energy to innovation activities and the local 
development processes (see. Bathelt et al. 2002, Storper & Venables 2002). 
Part of the dynamic capabilities affecting the development of industrial activity in a 
region is the ability of the local policy networks to support the innovation activities and 
growth of the firms. All regions have certain resources but not all of them are able to 
utilize them effectively (Sotarauta 2003, 8). Factors as a shared development view, the 
ability of local organisations to interact with each other and the ability to create 
consistent development measures.    
In this paper, I take a look at all these different external and internal factors each as 
elements that have enabled the local biotechnology industry to develop successfully in 
Turku region. With external factors, a general division into technological, institutional 
and economic factors is made. These factors are overlapping and often many of the 
factors have the elements of all of these. After that internal factors are analysed by 
looking at the development processes that have taken place in Turku in during the last 
10-15 years.  
Technology – the changes in the biotechnology and life sciences industry 
One of the most important factors enabling the growth of the biotech cluster in Turku 
has been the change in the technologies used especially in the pharmaceuticals. This so 
called biotechnology revolution has changed the industry structure. The paradigm shift 
from chemistry based to biology (e.g. genomics) based drug development created totally 
new phases at the beginning of the R&D process, which opened up new possibilities 
especially to SMEs. This change is mainly materialised in a shift in the dominant 
technology of the pharmaceutical field, from random screening to targeted drug 
discovery that emerged from bioengineering after the 1970s revolution.  
Genomics for example is making drug development more focused, cheaper and is 
making it possible to make more ‘tailored’ drugs for targeted groups of patients. For 
example the new biochip technology with the capacity to do testing at a friction of the 
cost of traditional screening. Prices of the drugs are mainly driven by drug development 
costs. Traditional drug discovery methods for medicinal chemistry of trial and errors are  
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being displaced by combinatorial chemistry where thousands of compounds can be 
screened for each gene target in search for the perfect drug. At the same time it is 
possibly to target specialized drugs for people with different kinds of genotypes. 
Another important new factor is the increasing use of modern ICT technology, which 
has also increasingly modified the research processes and opened up new possibilities 
e.g. for molecular research. 
The use of new technologies has then changed the industry structure. What once used 
to a right-moving value chain, i.e. with the highest value-added component being 
marketing and sales, has since the 1980s emerged as a labour specialisation with high 
value added at both extremes of the chain. In addition to the marketing and sales on the 
right end also drug discovery on the left has become more and more important – 
intellectual property and know-how have also become merchandise (Brännback et al 
2001b, 5). Although sales and marketing still tends to be the big money-earner, the shift 
in labour specialisation has resulted in an interdependency between two types of 
organisations, particularly exemplified by the U.S. example: small, dedicated biotech 
firms (DBFs) with proprietary technology platforms engaged in drug discovery (and 
occasionally development) and on the other end, mid-size to large pharmaceutical 
companies with many more functions vertically integrated and significantly more 
revenue-rich than the smaller DBFs. 
This “new way” of developing drugs has been one key factor that has given the small 
companies a possibility to enter the field previously dominated by large players. The 
new integration of different disciplines and the increasing importance of publicly 
generated scientific knowledge have increased the need for the Big Pharma to 
collaborate with universities and small start-ups or specialized companies. This new 
increasing interdependence between small discovery companies and large MNCs suits 
both parts. The small companies get resources, tools and a distribution channel as the 
big companies can increase their R&D productivity, spread their risks related to 
expensive R&D and have access to new knowledge and new innovations.  
From a spatial point of view the knowledge value chain is increasingly both local and 
global. Early phases like research and early exploitation of new discoveries are highly 
regionalised. Typically small companies are spin-offs from university or industry with a 
single product they want to bring to the market. This case applies also to Turku. These 
companies tend to locate near their knowledge base, which in this case are the local  
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universities and existing mid-size companies. The later development, distribution and 
marketing are highly globalised especially in pharmaceuticals but increasingly also in 
other fields like diagnostics and nutriceuticals.  
To sum it up, the emergence of new technologies and tools have changed the 
industry structure, increased the role of universities and R&D-institutions as sources of 
knowledge and opened up new possibilities for small start-up companies with 
specialised know-how. In Turku, these changes have been quite visible. Facing 
increasing global competition, the local mid-sized company Orion has moved 
increasingly from manufacturing and distribution to R&D and at the same time cut 
down the number of drugs in the pipeline. A few of these R&D-programs have since 
continued as independent DBFs. Also the co-operation between the universities and 
firms has increased drastically and the number of new specialised start-ups using 
modern biotechnology has grown significantly. 
Economic factors behind the transition 
Economic factors are closely related to technological change as the changes in 
technology have affected the way especially the pharmaceutical industry is reorganising 
itself. Economic factors affecting the development process are not limited to those 
affecting a particular industry but also general economic fluctuations can have big 
impact on the competitiveness of firms and the policy made by supranational, national 
and local policymakers.  
The main economic opportunity for new small companies comes from the problems 
encountered by the global pharmaceutical companies. The recent economic changes in 
the pharmaceutical industry can be summarised as: 
−  Impact of losses in patents has deteriorated the profits. Large pharmaceuticals 
are hard pressed to find new patentable “blockbusters” (Bureth 2002) 
−  There has also been a gradual decrease in the productivity in pharmaceutical 
R&D processes. This has been partly explained by the fact that the traditional 
methods like ‘random screening’ need more and more molecule candidates to be 
successful, which has increased expenditure. Other explanation has been the 
skills – old pharmaceutical R&D skills have been focused on chemistry based 
expertise and is there has been a lot of problems in turning these skills to more 
biology based.  
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−  There has also been a tremendous increase in R&D costs at the same time as 
market shares have dropped. The average cost of a new drug has been estimated 
to be over 800 million dollars and fewer and fewer drugs are able to cover their 
development costs (DiMasi et al 2003).  
As there are not enough blockbuster drugs in the pipeline, the development cost have 
gone up and the R&D productivity down, there has been a need to reorganise the whole 
development process. The outsourcing of R&D and services has become more common. 
In fact, interaction and different kinds of co-operative agreements are more common in 
biotechnology industries than in any other field (Hagedoorn, 1993). Companies sell 
different specialised services and intellectual property to other companies that further 
develop innovations. This has opened up many new opportunities for small and medium 
sized companies. Many of the new companies in Finland do not produce end products 
but usually intermediate products and services used by other members of the industry 
(Brännback et al 2001b, 24). 
From the SME point of view the most important economic factor, however, has been 
the development of venture capital (VC) markets in Finland during the 90s. This factor 
has been especially important for biotechnology firms since in biotechnology the R&D 
costs are very high and the typical time to markets for a product can be very long (10-12 
years in drug development). For many of the local company executives, the increased 
availability of VC in the mid 90s was one of the key factors that enabled the companies 
to grow. In Finland, in contrast to US, private VC has not played such a big part. The 
domestic private VC sector is still not very big and only a few foreign VCs have so far 
come to Finland. Therefore the public funded organisations and funds like Sitra have 
played a very big role in substituting the lack of foreign private VC. 
The more global economic factor for the whole life sciences is the steadily growing 
markets. Most of the markets are in the developed countries, where population is aging 
at the same time when the general income levels are steadily growing. In drugs, for 
example, the global market in 1999 was $350 billion, which was 11% more than a year 
before. The same applies to related fields like diagnostics. It has been estimated that by 
2010, global markets, including sectors where life sciences and biotechnology constitute 
a major portion of new technology applied, could amount to over EUR 2,000 billion 
(Commission of the European Communities 2002). At the same time the USA and  
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Japan alone cover more than 50% of all markets. This means that while profits from 
individual products are decreasing, the whole market is growing fast.   
One general economic element affecting the growth environment has also been the 
severe economic recession in Finland in the early 1990s. As a result thousands of 
companies and jobs were lost. The recession caused many structural changes both in 
companies but also public sector. Especially the public sector was activated to generate 
new jobs and in Finland, an innovation oriented approach was chosen. This meant 
increasing support for both public research and private firm and job generation. 
Partly as a result of the economic downturn the local government was also activated. 
The recession hit Turku harder than many other cities. The local industry had succeeded 
fairly well previously and thus there had been no real need for local activism in 
economic development. During the recession, many of the local industries had to face a 
serious restructuring, leaving Turku with a very high and persistent problem of 
unemployment. At the same time in many other Finnish university cities, the rise of ICT 
industry and especially Nokia provided a new path for success. However, Turku did not 
have a lot of education and research in ICT and the industry was also quite small. 
Something else had to be found and biotechnology is a very strong candidate for a new 
growth industry and policy initiatives were directed to support research and business in 
this area. 
Institutions – the changes in the innovation environment 
The local development of the biotechnology industry in Turku probably would not have 
happened in the current magnitude, had it not been the change especially in the national 
policy environment. Compared with some major biotechnology countries like the USA 
and the UK, the Finnish national innovation system is highly integrated but state led. 
The national innovation system plays a big role in the development of biotechnology 
industry in Finland. Most of the financing for the universities and the companies come 
from public sources and there are several dedicated programs at the national level to 
support biotechnology. Some sources even see that biotechnology will be the fourth 
pillar of the Finnish industry in the future. 
The Finnish model for supporting biotechnology can be described as ‘Science-led 
strategy from above’ (Cooke 2002, 24). In Finland the national innovation system has 
played a significant role in the development of the industry. It has important 
components supporting science based and resource intensive business, like Academy of  
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Finland funding basic research, TEKES applied research, development and knowledge 
transfer, Sitra providing funding and VTT conducting research. There are also public 
programs like Centres of Expertise co-ordinating and focusing resources in key 
industries in each region. 
The national innovation system in Biotechnology covers several institutions and 
organizations, many of which are located in Helsinki region. The most important of 
them are the ministries, the Academy of Finland and the Finnish Technology Agency 
TEKES. The biggest public sources of finance for biotechnology are the Ministry of 
Education, the Academy of Finland, the Ministry of Trade and Industry and TEKES. 
In the late 1980s, the ministry of education started the first research programme on 
biotechnology. Since then the amount public funding in the form of different research 
and technology programs, Centre of Excellence funding for universities and public VC 
has increased tremendously. The Finnish government has had a determined strategy to 
increase the amount R&D expenditures and has also channelled more and more public 
funding to support R&D activities. 
Biotechnology has been one of the key areas of public funding and institutional 
support. Biosciences cover roughly 40% in the national R&D budget. TEKES, the 
national technology agency has invested some $90 million in biotechnology, which 
accounts for 27% of the total investments. The Ministry Education has set new Centres 
of Excellence to universities and in 2000, nine of the 26 top units were in the field of 
Biotechnology. 
The impact of the changes in the national science and technology policy has been 
very remarkable also in Turku. The new dedicated university research units have 
received a lot of public funding; local actors have been active in the development 
programs. Also the public VC has played a big part in the growth of the new firms. 
However, in Turku the national institutions can be seen more to be in a position of 
resources for local activity rather than activators themselves. As it comes to visibility in 
the national policies, Turku remained quite invisible (compared with e.g. Helsinki) until 
the late 80’s. During that time (1987) the Ministry of Education launched a new 
research programme on biotechnology. In the first drafts were very Helsinki centred 
despite the fact that Turku was not much smaller in terms of biotechnology related 
activities. This ‘injustice’ raised local activity among the research community (Bruun et 
al 2001). This situation leading to local informal initiatives to increase the visibility of  
  17
Turku in terms of biotech activities can be seen as one of the turning points in 
recognising the opportunities to develop a local concentration of biotechnology. 
Local opportunities - the development of Biotechnology industry in 
Turku 
In addition to many external factors that have provided opportunities for the local 
industry to emerge and grow, local elements have also been crucial. The long-time 
development of the local knowledge base in biotechnology related fields, close 
interaction between knowledge providers and users but also local institutional 
innovations have all provided the local biotech activities a good breeding ground. 
First of all, the existing local capabilities have not appeared only lately, but have 
been accumulated over time. The current fast growth in terms of new companies has 
mainly happened during the last ten years, but the roots of the industry are much older. 
The first drug companies (Leiras and Farmos) were established in the 1940s. Also 
Wallac (nowadays part of the PerkinElmer group) was born during that time. These mid 
sized companies established the tradition of co-operation to some university groups and 
departments during the time when it was not that common in Finland. A good example 
of this is the diagnostic company Wallac that had a need for co-operation with the 
universities already in the 60s. They also had this need to make sure the availability of 
professional employees and the technology centre provided a good opportunity.  
These older and bigger companies have been a valuable asset for the concentration to 
build on. The bigger companies have had an influence that in the long run specialised 
expertise in business and development activities has been accumulated in the region. 
This is clearly illustrated by the fact that many key people in the smaller companies in 
Turku and even in the universities have been working at some point in the bigger 
companies. Bigger companies have also acted as a pool for the workforce as for many 
special services. In the case of Turku it seems, though, that the use of local services is 
small among the bigger companies. One important thing in the case of bigger 
companies in the region is that they have, in many cases acted as a pool for new start-
ups. Many ideas have been exported even by individual workers leaving the company 
but in some cases also by a dedicated spin-out strategy of the bigger company. 
Also the scientific knowledge base has not been developed overnight. Instead, many 
of the strong fields are based on studies started as early as in the 60s or 70s. In Turku, 
the level of scientific research in the biotechnology related fields has been of high level  
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with many research groups near the top of the world in their related fields. This has 
been a very important resource for the growth of biotech industry. It has been noted in 
several studies that in biotech, the performance the strength and width of the scientific 
base is perhaps the single most factor affecting the development of the industry (Breschi 
et al 2001). 
One of the important factors for new start-ups has been the strong academic linking 
to US. When the molecular biology revolution occurred in the 1970s, many PhDs and 
doctors from Turku did their postdoctoral research work in some of the best 
laboratories. During they stay they witnessed firsthand the birth of commercialised 
biotechnology and the many pathways through which academics became involved in the 
business of medicinal biotech. This appears to have been particularly important for a 
few lead researchers who subsequently came back to Turku and became intricately 
involved in the setting up of both the Centre for Biotechnology, as well as a few start-
ups which have been very promising.  
From a policy and resource point of view, one important factor in the rise of 
biotechnology has been that the low critical mass in IT-related skills and industry. This 
has led to the need for a concerted effort to foster its life-sciences research and 
commercialisation. The absence of engineering departments in the Turku city area 
(except for Chemical engineering at the Åbo Akademi which has been relevant to 
biotech) is often stated by academics, policy makers and entrepreneurs alike as the 
reason why no IT-boom occurred in Turku, unlike in many other Finnish cities.  
In addition to the long term development of capabilities, the developments in the local 
innovation environment during the past 15 years have been very important for the 
dynamics of the biotechnology industry. In general, this development can be seen as a 
modification of behaviour of key agents: local actors in business and academia, 
university administration and city government. 
The first change can be seen as happening in the local innovation network. The first 
seed can be seen from the late 80s. The first dedicated project for improving 
biotechnology research the South-West Finland Biotechnology project (SWB) started in 
the mid 80s. In addition to some scientific results, this can be seen as the first time when 
biotechnology was introduced as potential growth area. Approximately at the same time 
(1986) a Foundation of New Technology (FNT) was established. This was a very 
informal organisation, consisting of around 30 key people mainly from industry and  
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academia and originally intended to discuss about plans to establish first technology 
park idea the Data-City (Bruun et al 2001). This was the first bigger forum where key 
people could be brought in to the development process.  
The technology centre was the physical forum for building a cluster. What is 
interesting, that in Turku the city of Turku was not the initiator in starting a technology 
park. Of the 7 technology parks running in Finland in 1989 five were a result of the city 
government working centrally in the development process (Höyssä 2001, 29). Instead in 
Turku, the main initiators for new technology park initiatives, Data-City and later Bio-
City, were individual actors from academia and different business, most notably 
construction. On the other hand, the technology centre being strongly associated with 
real estate business put even more distance towards the city administration. 
Technology centre BioCity was the second stage of the local technology park 
concept. It was started in 1989 after a relatively successful ICT related DataCity. The 
successful forming of BioCity can be seen as a combination of different needs that were 
joined for a common platform. The real estate business saw a business opportunity in a 
new kind of a ‘technology concept’, some industry people saw an opportunity to get 
more contacts and influence in the co-operation with the universities and the university 
people saw an opportunity to get better resources for their research and education 
activities. Earlier positive experiences in starting an ICT related activity in the form of 
DataCity gave the actors more confidence for pursuing same kind of activities related to 
biotechnology. The universities saw that co-operation between them could work and the 
local decision makers were more aware of the new opportunities.  
The BioCity concept has been very important for the cluster in many ways. BioCity 
was not only a building for new companies to operate but also bigger concept. The 
original idea was to provide synergy between industry and academia by gathering a 
critical mass of researchers in different fields and technical resources together with each 
other and the companies (Bruun et al 2001). This was made by establishing new 
facilities and labs that were jointly administrated by two universities, the University of 
Turku and Åbo Akademi. From the universities point of view, however, this new kind 
of organisational innovation came not so much from a shared vision but from lack of 
resources which made the administration look for new ways of co-operation. Nowadays 
the whole BioCity Turku research community consists of over 50 research groups with 
over 500 people working in different fields.  
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The recession in Finland and in Turku in the early 90s activated more local actors 
and also the city government to look for new future industries to concentrate on. 
Compared with other mid-sized cities like Oulu, Tampere and Jyväskylä, Turku became 
active in the local economic development quite late. This has been partly a consequence 
of the local industrial structure – the impacts of economic restructuring in the 70s and 
80s were not as severe as in many other cities. The collapse of the Russian markets that 
was important for many local industries and the recession made also the local 
authorities to pay more attention to economic development issues. Since then, the city 
of Turku has been very active in promoting new industries and particularly 
biotechnology. The city has invested especially in infrastructure.  
Local authorities, alongside other actors, have also been active in supporting the 
national Centre of Expertise programme – a program which in Turku has brought new 
resources in organising co-operation especially biotechnology related areas. In general, 
all the local actors have been very active in using the opportunities provided by the 
national science and technology policy and regional policy. One element that shouldn’t 
be underestimated has also been the use of biotechnology as a spearhead branch in city 
marketing.  
To sum it up the local factors in Turku have been important in the process of 
building capacity. The most important local actors have been: 
−  Older Mid-size companies => early co-operation with the universities, 
employment base, spin-offs 
−  Local active key players in industry, research and real estate business => 
creating vision for development, activating local players, lobbying, acquiring 
resources 
−  High level university research 
−  City of Turku => Building infrastructure and supporting development in the late 
90s  
Conclusions 
The aim of this paper was to analyse the different aspects that have been affecting the 
birth and growth of biotechnology industry in Turku. The main argument was that 
instead of just looking at one factor, such as opportunities provided by technological 
change, the logic of spatial concentration of firms or public policy intervention, there is 
a need to see these different aspects as all being important for the successful 
development of a locally clustered industry. The study was based on assumption that the 
dynamics of the development process determine the way industry develops in a certain  
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location. The paper aims to show the way these different external and local factors are 
related to each other, affecting each other during the process. 
The driving local organisations and actors behind Turku’s upward trajectory in 
biotechnology have been its historical tradition in medicine, biology and chemistry that 
has formed a strong local science base. These, with intersections with the 
pharmaceutical and diagnostic firms have been driving the gradual economic success of 
Turku firms. Overall, because of the long-term relationships with university researchers 
established by mid-size pharmaceutical companies within Finland, both domestic and 
foreign, the industry-academic connections function relatively well. In addition, there 
has been an organisational proliferation of “new” types- hybrid research organisations 
heralding new forms of inter-university co-operation as well as new intersections with 
the private sector. In general it seems that knowledge transfer as well as knowledge 
spill-over effects have been in a quite important role for the development and spatial 
concentration of the cluster.  
The other remarkable local factor has been the activation of local development 
around biotechnology in the late 80s and early 90s. These coalitions have had a very big 
impact on launching a biotechnology related science park, forming new institutions to 
support biotechnology, mobilising local resources as well as lobbying for national 
resources. What has been remarkable in the birth of this local ‘development network’ is 
the almost total absence of public actors in the early stages of the process. Instead, the 
local activism has bread from various interest groups driving their own agenda inside a 
shared framework. 
In this paper, I argue that the local science base, long traditions in university-industry 
co-operation and strong policy networks have not been enough for a new biotechnology 
industry to emerge and grow in Turku. The success has also required favourable 
external conditions that have enabled the local capabilities to be converted to industrial 
activities. 
 The technological evolution especially in biology and ICT has especially changed 
the pharmaceutical industry structure. The role of universities and dedicated R&D 
organisations has increased in generating new knowledge. This has meant both 
increasing co-operation between industry and academia, and the increasing 
commercialisation of university research in the form of patents but also new-start up 
firms.  
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Technological change, legislation (especially IPR) and the increasing cost of drug 
design has also chanced the economic conditions around life sciences. The problems 
faced by large multinationals have forced them to change their behaviour, which in turn 
has opened up new possibilities for specialised R&D and service companies. Especially 
in Turku one economic factor has been the increasing financing for biotechnology firms 
in the form of VC in the 90s. Without this change the growth probably would not have 
been possible at least in biopharmaceuticals, which is the biggest sub-sector in Turku. 
Also the changes especially in the national Science and Technology policy and the 
national innovation system have been very important source for new resources. The 
amount of public funding to R&D has increased tremendously from the late 80s and this 
funding has been channelled in many ways to academic research, commercial R&D and 
public venture capital. This has been especially true in new emerging and growing fields 
like ICT and biotechnology, which have got a lion’s share of all public R&D funding. 
National organisations like the ministries, TEKES, Academy of Finland and Sitra have 
therefore had a very big impact also in the development of biotechnology industry in 
Turku as the local resources have been quite limited. 
If looking at the general critical factors for the cluster development, Turku fits quite 
well with the general picture found elsewhere. In the British study of Biotechnology 
Clusters (Biotechnology Clusters, 1999), several factors were identified that affect the 
development of biotechnology industry in a given location. If looking at the Turku case 
in this light, we can conclude that many of these factors have also been present in 
Turku. Below are the different factors and an evaluation of their significance in the case 
of Turku: 
i.)  Strong science base => In the recent international evaluation the science 
base in Turku was found of high level.  
ii.)  Entrepreneurial culture => A lot of new companies have been born. The 
general culture still not very entrepreneurial.  
iii.)  Growing company base => Company base has grown rapidly in many 
fields in the last part of the 90s, not many new DBFs in the past few years 
iv.)  Ability to attract key staff => So far the local and other Finnish universities 
have been able to provide staff. According to many companies a key 
problem in the future, especially for foreigners Turku too small and not 
very attractive. 
v.)  Availability of finance => Lack of MNCs and international VC. Domestic 
VC (especially public) has substituted international VC in the 90s. 
Recently VC money has been tighter and there have been big problems in 
attracting financing. Remote location and the lack of Finnish private VC a 
challenge.   
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vi.)  Premises and infrastructure => Good infrastructure. Public sector 
(especially the City) very active in supporting building new infrastructure 
recently. University funding has been very tight. 
vii.)  Business support services and large companies in related industries => 
Few larger companies that use local services. Many specialised services in 
Helsinki and abroad. Some good local services but the number is still quite 
small. 
viii.)  Skilled workforce => A Good level of education in the local universities.  
The long tradition in pharmaceuticals and diagnostics provides 
experienced people though not enough for specialised jobs. Especially lack 
of business expertise related to biotechnology and internationalisation. 
Small city size has a negative impact on the general functionality of the 
labour market. 
ix.)  Effective networks => Local networks working effectively and have been 
born voluntarily around issues, not formality. Global networks are quite 
wide.  
x.)  Supportive policy environment => National policy very important in 
providing financing both for research and commercial development. Local 
policy more important recently in supporting infrastructure. University 
policy and structures not hindering but not helping either. 
 
All in all, it can be concluded that the success story in Turku has so far been based on a 
combination of several factors related to the long term accumulation of biotech related 
capabilities, technological transition, economic factors and institutional factors. The 
opportunities provided by these external factors have not been enough, however, but 
strong local development activities have also been crucial in capitalising the 
opportunities rising from the changes in the external environment. 
If looking at the future challenges for the biotechnology industry in Turku, there are 
several factors that might prove problematic. First, the current success has so far been 
based on a science based approach. In Turku, the industry consists mainly of R&D 
industry related to research and development. This strategy is very risky and at the same 
time requires strong resources for continuing especially at the initial stage when there 
are now revenues from existing products or intellectual property. This danger is already 
evident as the global recession has cut down the financing for new start-ups in Turku 
and many of them have had to cut down their activities and personnel. 
To escape this trap seems difficult as there seems to be very little possibilities to 
build the whole value chain in a small region, where there is not so much variety in 
terms of skills, capabilities and firm-size. At the same time, the expectations especially 
among the policymakers are waiting for biotechnology to produce more jobs especially 
in manufacturing but it is unlikely that biotechnology will ever become a major  
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employer. Biotechnology cannot be new Nokia, because of the differences in the 
industries and opportunities. This is something that is a challenge to local policy 
making. Biotech is risky, expensive, does not employ unemployed people with low 
education and it is also fairly unlikely that biotechnology will ever bring any bigger 
production plants to the region. 
From spatial point of view there is also the question of size and critical mass in the 
future. Some of the late studies have shown that biotechnology is increasingly 
concentrated (at least in US) in few so megacentres. Turku is already facing serious 
competitions from the Finnish capital region Helsinki but also from other big regions in 
Europe and in US. It also seems to be difficult to get international companies, personnel 
and private VC to the region and therefore, despite dense international connections, the 
local cluster probably has to rely mainly on local human and financial resources also in 
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